T he mechanisms generating genetic associations have proven difficult to elucidate for most diseases because the vast majority of the pertinent variants are presumed to be components of a yet to be sufficiently understood regulome. Gene-environment interactions add another layer of complexity that may help explain the etiology of many autoimmune diseases 1-3 . In particular, Epstein-Barr virus (EBV) infection has been implicated in the autoimmune mechanisms and epidemiology of systemic lupus erythematosus (SLE) 4-7 , increasing SLE risk by as much as 50-fold in children 4 . SLE patients also have elevated EBV loads in blood and early lytic viral gene expression 6 . Despite suggestive relationships between EBV and multiple autoimmune diseases, the underlying molecular mechanisms remain unknown 8, 9 . Genome-wide association studies (GWAS) have identified > 50 convincing European-ancestry SLE susceptibility loci ( Fig. 1a ), providing compelling evidence for germline DNA polymorphisms altering SLE risk [10] [11] [12] [13] . As in most complex diseases, most SLE loci occur in likely gene regulatory regions 14, 15 . We therefore asked whether any of the DNA-interacting proteins encoded by EBV preferentially bind SLE risk loci. Our analyses identified strong associations with an EBV gene product (EBNA2), providing a potential origin of gene-environment interaction, along with a set of human transcription factors and cofactors (TFs), in SLE and six other autoimmune diseases. We present allele-and EBV-dependent TF binding interactions and gene expression patterns that nominate cell types, molecular participants and environmental contributions to disease mechanisms for these and 85 other diseases and physiological phenotypes.
Results
Intersection of disease risk loci with TF-DNA binding interactions. To identify TFs that bind a significant number of risk loci for a given disease, we developed the RELI (Regulatory Element Locus Intersection) algorithm. RELI systematically estimates the significance of the intersections of the genomic coordinates of plausibly causal genetic variants and DNA sequences bound by a particular TF, as determined through chromatin immunoprecipitation and sequencing (ChIP-seq). Observed intersection counts are compared to a null distribution composed of variant sets chosen to match the disease loci in terms of the allele frequency of the lead variant, the number of variants in the linkage disequilibrium (LD) block, and the LD block structure ( Fig. 2a and Supplementary Fig. 1 ; see Methods). RELI is an extension of previous methods such as XGR 16 , which estimates the overlap between an input set of regions and genome-wide annotations, although XGR does not explicitly replicate LD block structure in the null model.
We first gauged the ability of RELI to capture known or suspected relationships between TFs and diseases. The androgen receptor (AR) plays a well-established role in prostate cancer 17 , and RELI analysis showed that AR binding sites in the VCaP prostate cancer cell line significantly intersect prostate-cancer-associated loci (17 of 52 loci, relative risk (RR) = 3.7, Bonferroni-corrected P-value (P c ) < 10 −6 , Table 1 ). Similarly, binding sites for GATA3 in the MCF-7 breast cancer cell line significantly intersect breast-cancer-associated variants (P c < 10 −10 , Table 1 ), concordant with the established role of GATA3 in this disease 18 . Consistent with EBV contributing to multiple sclerosis (MS) [19] [20] [21] [22] , RELI showed that the EBV-encoded EBNA2 protein Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity occupies 44 of the 109 MS risk loci in the Mutu B cell line (P c < 10 −29 , Table 1 ). Prostate and breast cancer loci did not significantly intersect EBNA2 peaks, nor did the loci of certain inflammatory diseases such as systemic sclerosis (Table 1) . Collectively, these observations illustrate that predictions made by RELI are specific and consistent with previously established disease mechanisms.
We assembled 53 European-ancestry SLE risk loci (all with P < 5 × 10 −8 in case/control studies) with risk allele frequencies > 1%, in aggregate constituting 1,359 plausibly causal SLE variants (Supplementary Dataset 1). To explore the possible environmental contribution from EBV, we evaluated the ChIP-seq data from EBV-infected B cells for the EBV gene products EBNA1, EBNA2 (Table 1) . Thus, the associations we detect between SLE risk loci and EBNA2 cannot simply be explained by the previously established strong colocalization between SLE risk loci and B cell regulatory regions in the genome 23 . We next applied RELI to a large collection of human TF ChIP-seq datasets (1,544 experiments evaluating 344 TFs and 221 cell lines; Supplementary Dataset 2). In total, 132 ChIP-seq datasets involving 60 unique TFs strongly intersected SLE loci (10 −53 < P c < 10 −6 ). We chose a stringent corrected P-value cutoff of 10 −6 on the basis of results from a simulation procedure aimed at estimating the false positive rate of our approach (see Methods). Notably, 109 (83%) of the significantly associated ChIP-seq datasets were obtained in EBV-infected B cell lines, with high fidelity between datasets (Supplementary Dataset 3). Nearly identical results were obtained using a null model that also takes the distance to the nearest gene transcription start site into account ( Supplementary Fig. 2 ), and analogous results were obtained using the null model employed by the GoShifter 24 method ( Supplementary Fig. 3 ). Similar results were also obtained with an expanded set of all 83 SLE risk loci published to date (regardless of ancestry) [10] [11] [12] [13] or when separately examining SLE risk loci by ancestry ( Supplementary Dataset 3) . Strikingly, 20 of these 60 TFs participate in 'EBV super-enhancers' , which enable proliferation and survival of EBV-infected B cells 25 . The human TFs in question largely bind the same loci occupied by EBNA2, comprising an optimal cluster of 28 SLE risk loci ( Fig. 1a ).
If EBV is involved in SLE pathogenesis, then the absence of EBV, and hence EBNA2, should diminish the observed associations with SLE risk loci. For eight TFs, ChIP-seq datasets were available in both EBV-infected and EBV-negative B cell lines ( Supplementary Table 1 ). Notably, the four TFs with the strongest RELI P-values in EBV-infected B cells (BATF, IRF4, PAX5 and SPI1) had much weaker P-values in EBV-negative B cells (Fig. 1a, strongest RELI P-values were obtained in EBV-infected B cells, and none of the other cell types available for these TFs showed significant association (Fig. 1a , bottom right). For example, 22 ChIPseq datasets were available in EBV-infected B cells for the NF-κ B subunit RELA. Of these, 20 significantly intersected with SLE risk loci (10 −53 < P c < 10 −17 ), while none of the remaining 14 available RELA datasets in any other cell type had significant intersection. Previous studies have demonstrated that EBV activates the NF-κ B pathway, supporting the validity of this result [26] [27] [28] . Combined with the striking intersection between EBNA2 binding and SLE loci, these data strongly suggest an important role for EBV-infected, EBNA2-expressing B cells in SLE.
EBNA2-occupied genomic sites intersect autoimmune-associated loci.
We applied RELI to 213 diseases and phenotypes obtained from the US National Human Genome Research Institute GWAS catalog 29 and other sources (see Methods), and identified nine phenotypes displaying strong EBNA2 association with diseases in addition to SLE and MS: rheumatoid arthritis, inflammatory bowel disease (IBD), type 1 diabetes, juvenile idiopathic arthritis, celiac disease, chronic lymphocytic leukemia, Kawasaki disease, ulcerative colitis and immunoglobulin glycosylation (Supplementary Dataset 3). We designate the seven disorders among these with particularly strong EBNA2 associations (P c < 10 −8 ) the 'EBNA2 disorders' (see Fig. 1 ). A recent study performed statistical fine mapping of the variants for six of the seven EBNA2 disorders (IBD was not included) 30 . Of the resulting 1,953 candidate causal variants in that study, 130 overlap with EBNA2 ChIP-seq peaks in Mutu B cells (RR = 8.7, P c < 10 −132 ). Notably, this represents the second-ranked ChIP-seq dataset out of the 1,544 considered in our study, trailing only POLR2A ChIPseq performed in CD4 + T cells ( Supplementary Dataset 3) . Thus, the overlap between EBNA2 ChIP-seq peaks and loci associated with the EBNA2 disorders is even stronger when considering only statistically likely causal variants.
Consistent with the SLE results ( Fig. 1a) , the same TFs tend to cluster with distinguishing loci for each disorder (Fig. 1b-g and Supplementary Dataset 5). Further, there is also a stronger association in EBV-infected than in EBV-negative cells for many TFs, and the ten most associated TFs consistently intersect more strongly in EBV-infected B cells than in other cell types ( Fig. 1b-g and Supplementary Dataset 5). Hierarchical clustering identified a core set of 47 TFs binding to 142 risk loci across the seven EBNA2 disorders ( Supplementary Fig. 4 ). RBPJ, an established EBNA2 cofactor [31] [32] [33] , had the most similar binding profile to EBNA2 across loci, as expected.
NF-κ B proteins RELA, RELB, REL, NFKB1 and NFKB2 comprised many of the strongest associations with EBNA2 disorder loci (Supplementary Dataset 3). We therefore collected the 348 loci associated with at least one of the EBNA2 disorders and removed the 179 among these loci that contain at least one disease-associated variant located within a ChIP-seq peak for any NF-κ B protein in EBV-infected B cells. Among the remaining 169 loci, 19 still contained disease-associated variants falling within EBNA2 ChIP-seq peaks (2.15-fold enrichment, P = 0.00012), indicating that many of these loci may be occupied by EBNA2 independent of NF-κ B involvement.
To identify candidate EBNA2 cofactors, we isolated EBNA2 disorder-associated variants located within EBNA2 ChIP-seq peaks and evaluated them using RELI. This analysis confirmed the importance of RBPJ, followed by members of the basal transcriptional machinery (TBP and p300) and NF-κ B subunits (which are involved in EBNA2-mediated gene activation 34 ) ( Fig. 2b) . Interestingly, predicted EBNA2 cofactors varied with disease phenotype; for example, EBNA2 and EBNA3C were highly synergistic at the disease loci of three of the EBNA2 disorders (IBD, MS and celiac disease), but rarely coincided at loci for the other four diseases (Supplementary Dataset 6).
The particular TFs tend to be shared across the EBNA2 disorders, but the loci they occupy are less frequently shared. No EBNA2bound locus is associated with all seven EBNA2 disorders; most loci are unique to a single disorder ( Fig. 2c ). Thus, the loci occupied by EBNA2 in each disorder are largely distinct from one another. One counterexample involves the IKZF3 locus encoding the Aiolos TF, a key regulator in B lymphocyte activation 35 , with genetic variants from five different EBNA2 disorders intersecting EBNA2 ChIP-seq peaks ( Supplementary Fig. 4 ).
If changes in gene regulation explain these results, then expression quantitative trait loci (eQTLs), ChIP-seq peaks for RNA polymerase II and histone marks associated with active gene regulatory regions should be relatively concentrated at the risk loci occupied by EBNA2. These predictions are indeed true for each of the seven EBNA2 disorders ( Fig. 2d and Supplementary Dataset 3). For example, < 1% of all common variants in the human genome are eQTLs in EBV-infected B cell lines ( Fig. 2d , left panel, blue bars). This value rises to 2.3% for common variants located within open chromatin in EBV-infected B cell lines (red bars), and rises further to 2.7% for common variants within EBNA2 ChIP-seq peaks (black bars). Thus, there is a slight trend for a common variant located within an EBNA2 ChIP-seq peak to influence gene expression in EBV-infected B cell lines. Strikingly, this relationship is > 10-fold increased for EBNA2 disorder-associated variants: 27.8% of EBNA2 disorder variants that are located within EBNA2 ChIP-seq peaks were also eQTLs ( Fig. 2d , right panel, black bars), a value significantly greater than the fraction of EBNA2 disorder variants located within open chromatin in EBV-infected B cell lines (20.5%; P < 10 −5 , Welch's one-sided t-test) (red bars) or EBNA2 disorder variants in general (10.4%; P < 10 −8 ) (blue bars). Similar trends held for the other data types examined (Fig. 2d ). In aggregate, these results hint at the potential magnitude of the environmental influence of EBNA2 on host gene expression within EBNA2 disorder loci in EBV-infected B cells.
EBNA2 participates in allele-dependent formation of transcription complexes at disease risk loci. The observed associations ( Fig. 1) are genetic if and only if they are driven by causal allele-dependent differences. Since EBNA2 imitates the binding of NOTCH to RBPJ 36 , genetic variants at these loci could alter the binding of RBPJ (or another TF to which EBNA2 binds) or enable allele-dependent binding of a TF that requires modulation of the local chromatin environment by EBNA2 ( Fig. 3a) . Reanalysis of ChIP-seq data provides a means to identify allele-dependent protein binding events on a genome-wide scale; in cases where a given variant is heterozygous in the cell assayed, both alleles are available for the TF to bind, offering a natural control for one another since the only variable that has changed is the allele. We therefore developed the MARIO (Measurement of Allelic Ratios Informatics Operator) pipeline to identify allele-dependent protein binding by weighing imbalance between the number of sequencing reads for each allele of a given genetic variant, the total number of reads available at the variant, and the number and consistency of available experimental replicates (see Methods). MARIO is an easy-to-use, modular tool that extends existing methods 37-40 by (i) calculating a score that explicitly reflects reproducibility across experimental replicates, (ii) reducing run time by using multiple computational cores and (iii) allowing the user to directly provide genotyping data as input.
To identify heterozygotes for analysis, we genotyped five EBVinfected B cell lines with available ChIP-seq data and performed genome-wide imputation (see Methods). We applied MARIO and a related method, ABC 37 , to a deeply sequenced (~190 million reads) GM12878 ATAC-seq (Assay for Transposase-Accessible Chromatin and sequencing) dataset (GEO accession GSM1155957) and observed strong agreement between the 2,214 resulting scores (Spearman correlation 0.98, P < 10 −15 ). We next applied MARIO to 271 ChIP-seq datasets obtained in one of the five genotyped cell lines, altogether assessing 98 different molecules. Since EBNA2 binds DNA indirectly as a cofactor, we first asked whether the variants displaying EBNA2 allele-dependent binding might coincide with similarly altered binding of other TFs. This analysis identified strong concordance of allele-dependent binding events both within and across cell types. For example, we identified 68 heterozygous common variants located within alleledependent EBNA2 GM12878 ChIP-seq peaks. EBF1, whose binding is globally influenced by EBNA2 36 , has a coincident ChIP-seq peak favoring the same allele at 39 (57%) of these loci, as opposed to only 8 (11%) on the opposite allele (P < 10 −4 , binomial test, Fig. 3b ). Similar results were obtained when pairing EBNA2 binding in GM12878 with EBNA2 binding in Mutu cells, with established partners SPI1 and RBPJ, or with ATAC-seq chromatin accessibility data (Fig. 3b ). Analogous results were obtained for EBNA2 ChIP-seq data in Mutu and IB4 cell lines ( Supplementary Fig. 5 ). In total, MARIO confidently identified 21 variants associated with 15 different autoimmune diseases displaying allele-dependent EBNA2 binding in at least one cell type ( Table 2 and Supplementary Dataset 7) . We note that the number of heterozygous autoimmune variants for which EBNA2 prefers one allele over the other was not significantly more than expected by chance (see Methods). We also note that several variants might involve the HLA genes, and the current view is that coding alleles in the HLA class II in general are likely (though not certainly) causal for autoimmune diseases. Nevertheless, most of these variants are also involved in allele-dependent host protein binding, chromatin accessibility or presence of histone marks such as acetylation of histone H3 on Lys27 (H3K27ac) ( Supplementary  Dataset 8) . Together, these results suggest that many autoimmuneassociated variants may act by modifying host gene regulatory programs via altered binding of EBNA2 and other proteins.
To detect potential downstream effects of allele-dependent EBNA2 binding, we measured genome-wide gene expression levels by RNA-seq in Ramos, an EBV-negative B cell line that can support EBV infection. We confirmed the expected presence or absence of EBNA2 by sequencing (Methods) and western blot ( Supplementary  Fig. 6 ). We identified 80 genes with significant EBV-dependent alterations in gene expression ( Supplementary Dataset 9) , confirming that EBV modulates the expression of human genes. These results are highly consistent with a previous gene expression study and the literature (see Methods).
We next searched for autoimmune-associated variants that might affect EBNA2 binding, resulting in allele-dependent expression of a nearby gene. This analysis was dependent on the small subset of genetic variants satisfying four necessary criteria: the variant must be (i) plausibly causal for an autoimmune disorder; (ii) immunoprecipitated by EBNA2 antibodies; (iii) heterozygous in the cell line assayed; and (iv) proximal to a plausible target mRNA that contains a heterozygous variant in Ramos cells (to detect allele-dependent expression). For example, the 21 EBNA2 variants listed in Table 2 satisfy the first three criteria, but only 5 satisfy the fourth criterion of being within 50 kb of a potential target gene containing a heterozygous variant in the Ramos cell line. Despite these limitations, our approach identified autoimmuneassociated variants displaying allele-dependent EBNA2 binding and allele-dependent expression of a nearby gene. For example, rs3794102, a variant strongly associated with vitiligo (P < 10 −9 for case/control association), had significantly skewed allele-dependent binding of eight proteins; EBNA2, its suspected cofactor EBF1 36 and chromatin accessibility all favored the non-reference 'G' vitiligo risk allele (Fig. 3c , Table 2 and Supplementary Dataset 8) . Intriguingly, the proteins favoring the 'G' allele are considered activators, whereas the two proteins favoring the ' A' allele are repressors, suggesting that the variant and virus might act synergistically as an allelic switch. rs3794102, which is located within an intron of SLC1A2 (a gene for which we detected no RNA-seq reads), loops to the promoter of the neighboring CD44 gene as assessed by Hi-C experiments performed in GM12878 cells ( Supplementary Fig. 7 ). rs3794102 is also an established eQTL for CD44 in EBV-infected B cell lines (P < 10 −11 , MRCE dataset, RTeQTL database 41 RELB  NFKB2  ATF2  IRF4  RBPJ  RUNX3  EBNA2  MTA3  POU2F2  BCL11A  PAX5  TBP  RELB  NFATC1  IKZF1  VDR  BCL3  EBF1  NFIC  SP1  NFATC2  NELFA  WRNIP1  HMGN1  TCF12  MED1  MEF2A  ELF1  MAZ  TAF1  SIN3A  SPI1  RELA  NFKB1  CEBPB  NIPBL  YY1  CHD2  PML  STAT5A  TBL1XR1  BRD4  POLR2A  MYC  MAX  IRF1  SMAD1  BHLHE40  EP300 CLL (EU) TAL1  ARID3A  CCNT2  TEAD4  RCOR1  NR2F2  SIRT6  HDAC2  SMARCB1  SMARCA4  STAT2  TRIM28  ATF1  PRAME  JUN  REST  GATA1  GATA2  STAT1 
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Fig. 4 | Cell types and TFs at disease-associated loci. a, SLE variants significantly intersect H3K27ac-marked regions in EBV-infected B cells. H3K27ac
ChIP-seq peaks were collected from 175 different cell lines and types. The y axis indicates the negative log of the RELI P-value for the intersection of SLE-associated variants with the H3K27ac peaks contained in each dataset. b, SLE variants intersect active chromatin regions in EBV-infected B cells. Same as a, but instead using active chromatin regions, which are based on combinations of histone marks 44 . c, Global view of RELI results showing all diseases against all TFs. Columns and rows show the 94 phenotypes or diseases and 212 TFs with at least one significant (P c < 10 −6 ) RELI result. Color indicates negative log of the RELI P-value. TFs that participate in EBNA2super-enhancers [25] are colored red at the right. CLL, chronic lymphocytic leukemia; IgG, immunoglobulin glycosylation; CelD, celiac disease; UC, ulcerative colitis; IBD, inflammatory bowel disease; T1D, type 1 diabetes; RA, rheumatoid arthritis; MS, multiple sclerosis; SLE, systemic lupus erythematosus; EU, European ancestry; AS, Asian ancestry; union, all ancestries. d, TFs intersecting breast cancer loci. Intersection between disease loci with TF-bound DNA sequences (as in Fig. 1 presence of EBNA2 42 . In our experiments, CD44 expression was 6.8fold higher in EBV-infected Ramos cells compared to uninfected Ramos cells (P = 0.00015, Supplementary Dataset 9 ). Further, we identified a heterozygous genetic variant (rs8193) in strong LD with rs3794102 (r 2 = 0.87) located within the CD44 gene body, with 12 'T' allele RNA-seq reads and only 5 'C' allele reads in EBV-infected Ramos cells and no detectable reads in Ramos cells lacking EBV (Supplementary Dataset 10). We independently confirmed this result with allelic quantitative PCR (qPCR), observing a significantly higher expression for the T relative to the C allele in EBV-infected Ramos cells, with significantly lower expression in the absence of EBV (Fig. 3d ). CD44 is a transmembrane glycoprotein involved in B cell migration and activation. Taken together, these results suggest that the 'G' vitiligo risk allele enhances formation of an EBNA2-dependent gene activation complex, resulting in elevated expression of CD44 and consequent increased B cell migration and/or activation. We also identified a variant (rs947474) associated with type 1 diabetes and rheumatoid arthritis ( Table 2 ) located near PRKCQ, another gene with allele-and EBV-dependent expression in our data ( Supplementary Dataset 10) . Intriguingly, PRKCQ plays an established role in activation of the EBV lytic cycle 43 . Together, these examples establish that multiple autoimmune variants may alter binding events of protein complexes containing EBNA2 and host proteins, resulting in EBV-controlled allele-dependent host gene expression.
Autoimmune-associated genetic mechanisms in EBV-infected B cells.
We next used RELI to rank cell types by their relative importance to each of the EBNA2 disorders, on the basis of the intersection between disease-associated variants and likely regulatory regions in that cell type. This procedure identified a clear enrichment for EBVinfected B cells in SLE. For example, of the 175 H3K27ac ChIP-seq datasets available, the highest ranked 30 datasets were all from EBVinfected B cell lines (Fig. 4a) . Analogous results were obtained for 'active chromatin marks' (a model based on combinations of various histone marks 44 ) (Fig. 4b ), H3K4me3 and H3K4me1, for SLE and the other seven EBNA2 disorders ( Supplementary Datasets 3 and 11) . Collectively, these results support the EBV-infected B cell being an origin of genetic risk for each of the seven EBNA2 disorders. This analysis also highlights a likely involvement of other immune cell types in these disorders, including T cells, natural killer cells and monocytes ( Supplementary Dataset 3) . Although there are limited TF ChIP-seq data available for these cell types, one or more of the EBNA2 disorders were associated with 17 of the available T cell TF ChIP-seq datasets ( Supplementary Dataset 3) . Further, several EBNA2 disorder loci appear to be specific to T cells. For example, six MS-associated loci are largely T cell-specific, collectively intersecting 67 T cell ChIP-seq datasets, compared to only 12 EBV-infected B cell datasets for these same loci (Supplementary Dataset 12) . Together, these results are consistent with multiple shared regulatory mechanisms acting across autoimmune risk loci, some common between cell types (for example, B and T cells) and others being exclusive to a certain cell type.
RELI identifies relationships between particular TFs and many diseases.
Extension of RELI analysis to GWAS data for 213 phenotypes identified 2,264 significant (P c < 10 −6 ) TF-disease relationships ( Supplementary Datasets 1 and 3) . In addition to the EBNA2-related associations, clustering of these results shows a large grouping of hematopoietic phenotypes and well-established blood cell regulators such as GATA1 and TAL1 (Fig. 4c) . Other associations suggest additional mechanisms, many of which are supported by independent lines of evidence from other studies, such as GATA3, FOXA1 and TCF7L2 in breast cancer (Fig. 4d) and AR, NR3C1 and EZH2 in prostate cancer (Supplementary Dataset 3) . In total, application of these methods produced results nominating global disease mechanisms for 94 different diseases or phenotypes ( Supplementary Dataset 3) , providing new directions for understanding their origins.
Discussion
Our efforts to understand the gene-environment interaction between SLE loci and EBV have shown that EBNA2 and its associated human TFs occupy a substantial fraction of autoimmune risk loci. In particular, NF-κ B subunits such as RELA, RELB, NFKB1 and NFKB2 also strongly intersect many of these loci, suggesting that NF-κ B is important in the mechanisms that confer risk in these inflammatory diseases. Further analyses suggest that multiple causal autoimmune variants may act through allele-dependent binding of these proteins, resulting in downstream alterations in gene expression. In this scenario, the relevant TFs and gene expression changes must occur in the cell type that alters disease risk. Collectively, our data identify the EBVinfected B cell as a possible site for gene action at select loci in multiple autoimmune diseases (Fig. 1) , with the caveat that existing data are biased, having been predominantly collected in this cell type.
Notably, 4 of the top 20 TFs that co-occupy EBNA2 disorder loci with EBNA2 (MED1, p300, NFKB1 and NFKB2) can be targeted by at least one available drug 45 , and a recent study shows that the C-terminal domain of the BS69 (ZMYND11) protein can bind to and inhibit EBNA2 46 . These results offer promise for the development of future therapies for manipulating the action of these proteins in individuals harboring risk alleles at EBNA2-bound loci.
Our current data nominate particular TFs and cell types for 94 phenotypes, providing mechanisms for experimental verification and exploration that may explain the molecular and cellular origins of disease risk. As new genetic association and TF binding data are collected, approaches such as this will undoubtedly identify further disease mechanisms.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41588-018-0102-3.
Collection and processing of datasets. Phenotype-associated genetic variants were largely obtained from the NHGRI GWAS catalog 29 . This catalog does not contain candidate gene studies, including those from the widely used ImmunoChip platform 60 . Thus, for SLE, MS, systemic sclerosis, rheumatoid arthritis and juvenile idiopathic arthritis, peer-reviewed literature was curated (Supplementary Dataset 13). Only genetic associations exceeding genome-wide significance (P < 5 × 10 −8 ) were considered. Datasets were separated and annotated by ancestry, except where noted. Only phenotypes with five or more associated loci separated by at least 500 kb were considered, following Farh et al. 30 . Loci were anchored by the single most strongly associated variant and expanded to incorporate variants in strong linkage disequilibrium (LD) (r 2 > 0.8) using PLINK 61 , collectively constituting the plausibly causal variants. Final variant lists for each disease and phenotype are provided ( Supplementary Dataset 1) .
Functional genomics data were obtained from ENCODE 62 (downloaded April 2014), Roadmap epigenomics 63 (July 2015), Cistrome 64 (December 2015), PAZAR 65 (April 2014), ReMap-ChIP 66 (August 2015) and Gene Expression Omnibus 67 (Supplementary Dataset 2) . ChIP-seq datasets containing less than 500 peaks were removed. eQTLs were obtained from GTExPortal 49 (January 2016), the Pritchard lab eQTL database (http://eqtl.uchicago.edu/) (April 2014) and the Harvard eQTL database (https://www.hsph.harvard.edu/liming-liang/software/eqtl/) (April 2014). TF binding motif models were obtained from Cis-BP (build 1.02) 68 .
Regulatory Element Locus Intersection (RELI). RELI takes a set of genetic variants as input, expands the set using LD blocks and calculates the statistical intersection of the resulting loci with every dataset in a compendium (for example, ChIP-seq datasets) ( Fig. 2a and Supplementary Fig. 1 ). In Step 1, sequencing data from 1000 Genomes 69 are used to identify all variants with linkage (r 2 > 0.8) to any input variant within each major ancestry (European, African, Asian), thereby assigning them to LD blocks. In Step 2, overlapping genomic coordinates determine whether an observed intersection is recorded between each LD block and each dataset. In Step 3, the expected intersection is estimated between each LD block and each dataset. The most strongly associated variant is chosen as the reference variant for the LD block. A distance vector is generated providing the distance (in bases) of each variant in the LD block from this reference variant. A random genomic variant with approximately matched allele frequencies to the reference variant is then selected from dbSNP 70 , and genomic coordinates of artificial variants are created that are located at the same relative distances from this random variant using the distance vector. Members of this artificial LD block are intersected with each dataset, as was done for the observed intersections. This strategy accounts for the number of variants in the input LD block and their relative distances, while prohibiting 'double counting' due to multiple variants in the block intersecting the same dataset. We repeat this procedure 2,000 times, generating a null distribution with stable P-values. The expected intersection distributions are used to calculate z-scores and P-values for the observed intersection. The final reported P-values are Bonferroni-corrected (P c ) for the 1,544 TF datasets tested. We calculate the relative risk by dividing the observed intersection by the mean expected intersection. We also considered a higherstringency null model that only considers variants located within DNase-seq peaks in any of the 22 available EBV-infected B cell line datasets, which controls for the known association of autoimmune variants and B cell regulatory regions 23 .
We validated the RELI procedure as follows. First, we compared the z-scorebased P-values produced by RELI to empirically calculated P-values. We selected 187 ChIP-seq datasets with European SLE GWAS RELI corrected P-values that are evenly distributed between 1 and 10 −7 . An upper bound of 10 −7 was chosen due to the amount of time required to run the simulations. Overall, we observe very strong concordance between these 187 empirically derived P-values and the P-values estimated by RELI ( Supplementary Fig. 8a) , with a Pearson correlation coefficient of 0.82 (P < 10 −45 ). We also performed 200,000,000 simulations examining the EBNA2 Mutu ChIP-seq vs. European SLE variant relationship. Across these simulations, we observed a maximum of 16 loci intersecting EBNA2 Mutu ChIP-seq peaks ( Supplementary Fig. 8b ), conservatively setting an empirically determined P-value lower bound at 5 × 10 −9 and further supporting our estimated P-value of P c < 10 −24 for the 26 observed locus intersections. To validate our choice of 2,000 simulations, we compared the P-values obtained for the 187 datasets when using 2,000 vs. 5,000,000 simulations. Nearly identical P-values were obtained ( Supplementary Fig. 8c ).
We also estimated RELI false positive rates. We first generated a 'false library' of 1,544 ChIP-seq datasets that match the real library by randomly repositioning each peak within the genome. This random false library of ChIP-seq results matches the number of datasets, the number of peaks each dataset contains and the width of those peaks. Upon running the European SLE variants with RELI using 10 different false libraries, only one of the 15,440 datasets achieved a P-value less than our P c < 10 −6 threshold ( Supplementary Dataset 3) . Further, the P-value for this dataset (P c < 10 −8 ) is much less significant than those for EBNA2, RELA, etc. (P c < < 10 −20 ). We thus estimate our overall false positive rate to be ~1/15,440 (~0.006%).
Identification of optimal clusters. We identified optimal clusters (red outlines in Fig. 1 ) by comparing the observed number of TF-locus intersections to results from simulations. First, loci (x axis) and TFs (y axis) were sorted in decreasing order of the number of intersections (colored boxes in the heat map). We then iteratively considered every possible submatrix boundary, starting at the upper left corner. In each trial, the total number of intersections is kept fixed, but the locations of the intersecting positions are randomly permuted across loci. A Gaussian null distribution was obtained from 10,000 random trials. P-values were calculated for each submatrix by comparing the observed number of intersections within the submatrix to the null distribution, using a standard z-score transformation. The optimal cluster was defined as the submatrix with the best P-value.
that are contained in the reproducible variant set as a function of num_reads ( Supplementary Fig. 11a ). At this stage, this fraction still accounts for all variants, both allele-dependent and non-allele-dependent. We therefore adjust each curve by the normalized cumulative frequency of non-allele-dependent variants within the given range. For example, consider the WS_ratio = 0.3 curve ( Supplementary  Fig. 11a ). Each point on this curve is divided by a single value representing the normalized cumulative frequency of the non-reproducible variants, which is obtained from the y axis at the x = 0.3 position in the WS_ratio plot depicted in Supplementary Fig. 10d . Before dividing, 1 is added to this value to avoid divide-by-zero errors. Collectively, this approach selectively penalizes non-alleledependent behavior by accounting for the proportion of non-allele-dependent variants within each curve. These values were averaged across the seven datasets, yielding the final ARS values. This entire procedure is repeated for the cases of one, two or three available replicates, generating the points shown in Supplementary  Fig. 11b . Curves were fit to these points using a saturating function:
where w is the WS_ratio, r is num_reads and A w and B w are the fitting parameters. The resulting functions yield ARS values for any given heterozygous variant in any dataset as a function of the number of experimental replicates, the WS_ratio and num_reads. When multiple replicates are available, we only report an ARS value for a variant if the strong allele is consistent in the majority of cases. A direct interpretation of the ARS values can be seen in the relationship between ARS values and the WS_ratio ( Supplementary Fig. 11c ).
Statistical significance of the number of EBNA2 allele-dependent binding events. We observed 21 cases of allele-dependent EBNA2 binding to an autoimmune risk variant ( Table 2 ). To establish the statistical significance of this observation, we collected the full set of 42 autoimmune-disease-associated variants that are (i) located within a ChIP-seq peak in at least one of the three available EBNA2 datasets and (ii) heterozygous in the cell type from which that peak was obtained. This set represents all autoimmune variants for which we could have observed allele-dependent EBNA2 binding. We next created a pool of non-autoimmune-associated variants that also meet the above two requirements (resulting in a total of 4,160 variants). For each of the 42 autoimmune variants, we chose a corresponding non-autoimmune variant from this pool while approximately matching for the total number of EBNA2 ChIP-seq reads in the peak (within 10% of the read count). This procedure thus creates a matched set of 42 non-autoimmune variants that have an equal chance of resulting in alleledependent EBNA2 behavior. There were a sufficient number of variants to repeat the above procedure ten times without replacement. In total, we observed 256 significant EBNA2 allele-dependent binding events across these matched nonautoimmune variant sets, which is not significantly different from the frequency that we observed with the autoimmune variants.
EBV infection of Ramos cells.
All cells were confirmed to be free of mycoplasma infection using PlasmaTest (InvivoGen). Wild-type EBV was prepared from supernatants of B95-8 cells cultured in RPMI medium 1640 supplemented with 10% FBS for 2 weeks. Briefly, the cells were pelleted and the virus suspension was filtered through 0.45 μ m Millipore filters. The concentrated virus stocks were aliquoted and stored at -80 °C. We infected ~2 × 10 6 Ramos cells (ATCC CRL-1596) in the presence of growth medium containing 2 μ g/ml of phytohemagglutinin for 4 h. The infected cells were washed, cultured in growth medium and observed daily for multinuclear giant cell formation and morphological changes characteristic of EBV-infected B cells. After ten passages, infection was confirmed by measuring the expression of viral EBNA2 protein levels ( Supplementary Fig. 6 ).
RNA-seq.
RNA was isolated from Ramos cell lines with and without EBV infection using the mirVana Isolation Kit (Ambion). RNA sequencing targeting 150 million mappable, 125-bp reads from paired-end, poly(A)-enriched libraries was performed at the CCHMC DNA Sequencing and Genotyping Core Facility. Sequencing reads were aligned to the GrCh37 (hg19) build of the human genome using TopHat 74 and Bowtie2 73 with Ensembl 75 RNA transcript annotations as a guide. In parallel, these data were aligned to the EBV genome (NCBI). As expected, 0 reads mapped in the EBV-negative dataset, whereas 7,349 reads mapped in the EBV-infected dataset. 82.8% of the sequence reads aligned specifically to the human transcriptome, with a 2.6% increase in the aligned reads in the EBVnegative samples. No abnormal quality control flags were identified following QC analysis with the software FastQC (http://www.bioinformatics.babraham.ac.uk/ projects/fastqc/). For allelic analysis, sequencing reads were aligned to the GrCh37 (hg19) build of the human genome using Hisat2 76 . Differential expression analysis was performed using Cufflinks 77 .
As additional quality control, we further compared our results to a study examining host gene expression changes to EBV infection in primary B cells 28 . Of the 80 genes whose expression was significantly altered by the presence of EBV in our study, 18 of them are also significantly differentially expressed in this dataset.
Further, among the 80 differentially expressed genes we detected, many of them represent classic host genes whose expression is modulated by EBV. Genes whose expression is concordantly activated by EBV include CD44 78 , TNFAIP2 79 , MX1 80 and IFI44 81 ; genes with lowered expression include VAV3 82 and CD99 83 .
Allelic qPCR. gDNA and RNA were extracted from Ramos cells with and without B95.8 EBV infection using the DNeasy Blood & Tissue Kit (Qiagen) and mirVana miRNA Isolation Kit (Invitrogen), respectively. RNA was treated with DNase using the TURBO DNA-free Kit (Ambion) and converted to cDNA using the High-Capacity RNA-to-cDNA Kit (Applied Biosystems). qPCR was performed with a single set of Taqman genotyping primers (Applied Biosystems) to rs8193 using the ABI 7500 PCR system. Fold change of expression was calculated with 2 -ΔΔCT values, where cDNA was normalized to gDNA.
Statistical analyses. Details on statistical analyses are described in the corresponding sections. For statistical details on RELI and MARIO, see the corresponding sections above. The number of replicates or data points is provided in the figures and legends. Data are represented as means ± 1 s.d., unless otherwise noted.
Reporting Summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this article.
Data availability. RNA-seq data are available in the Gene Expression Omnibus (GEO) database under accession number GSE93709. Full datasets and results, including disease variants (with alleles) and all RELI and MARIO output, are provided in the Supplementary Information.
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Experimental design 1. Sample size
Describe how sample size was determined.
We determined sample size based upon available data and power calculations. Please see Supplemental Methods: "Collection and Processing of Datasets" "Cell line genotyping and imputation" sections.
Data exclusions
Describe any data exclusions. Data was excluded if it did not meet explicit quality control criteria. Please see. Supplemental Methods: "Collection and Processing of Datasets" "Cell line genotyping and imputation" sections. These sections were sent as a word doc with the pdf form.
Replication
Describe whether the experimental findings were reliably reproduced. The findings were replicated across multiple diseases and cell types (please see Figure 1 and Supplementary Tables).
Randomization
Describe how samples/organisms/participants were allocated into experimental groups. This is not applicable. We used pre-identified genetic variants and showed enrichment of TF binding based on pre-identified ChIP results.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Investigators were blinded to the risk/non-risk alleles during "prefered allele" analysis. Investigators were blinded to risk allele in luciferase studies.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly.
A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. p values) given as exact values whenever possible and with confidence intervals noted A summary of the descriptive statistics, including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
